Filters
Results 1 - 10 of 15
Results 1 - 10 of 15.
Search took: 0.024 seconds
| Sort by: date | relevance |
[en] The Heidelberg Ion-Beam Therapy Center will start clinical operation in spring 2008. Two horizontal beam lines and one isocentric ion gantry will allow for treating patients with ions ranging from protons to oxygen. While the building construction has been completed and beam is already supplied to the horizontal beam lines, currently the raster scanning system is implemented and the beam delivery system is commissioned. The status of the facility will be presented including current medical physics aspects
Journal
Verhandlungen der Deutschen Physikalischen Gesellschaft; ISSN 0420-0195; 
; CODEN VDPEAZ; v. 43(1); [1 p.]
; CODEN VDPEAZ; v. 43(1); [1 p.]
No abstract available
Journal
Verhandlungen der Deutschen Physikalischen Gesellschaft; ISSN 0420-0195; ; CODEN VDPEAZ; v. 41(2); [1 p.]
; CODEN VDPEAZ; v. 41(2); [1 p.]
No abstract available
Journal
Verhandlungen der Deutschen Physikalischen Gesellschaft; ISSN 0420-0195; ; CODEN VDPEAZ; v. 41(2); [1 p.]
; CODEN VDPEAZ; v. 41(2); [1 p.]
[en] The Heidelberg Ion Therapy Center (HIT) started clinical operation in November 2009. In this report we present the first 80 patients treated with proton and carbon ion radiotherapy and describe patient selection, treatment planning and daily treatment for different indications. Patients and methods. Between November 15, 2009 and April 15, 2010, 80 patients were treated at the Heidelberg Ion Therapy Center (HIT) with carbon ion and proton radiotherapy. Main treated indications consisted of skull base chordoma (n = 9) and chondrosarcoma (n = 18), malignant salivary gland tumors (n=29), chordomas of the sacrum (n = 5), low grade glioma (n=3), primary and recurrent malignant astrocytoma and glioblastoma (n=7) and well as osteosarcoma (n = 3). Of these patients, four pediatric patients aged under 18 years were treated. Results. All patients were treated using the intensity-modulated rasterscanning technique. Seventy-six patients were treated with carbon ions (95%), and four patients were treated with protons. In all patients x-ray imaging was performed prior to each fraction. Treatment concepts were based on the initial experiences with carbon ion therapy at the Gesellschaft fuer Schwerionenforschung (GSI) including carbon-only treatments and carbon-boost treatments with photon-IMRT. The average time per fraction in the treatment room per patient was 29 minutes; for irradiation only, the mean time including all patients was 16 minutes. Position verification was performed prior to every treatment fraction with orthogonal x-ray imaging. Conclusion. Particle therapy could be included successfully into the clinical routine at the Dept. of Radiation Oncology in Heidelberg. Numerous clinical trials will subsequently be initiated to precisely define the role of proton and carbon ion radiotherapy in radiation oncology.
Journal
Acta Oncologica (online); ISSN 1651-226X; ; v. 49(7); p. 1132-1140
; v. 49(7); p. 1132-1140
[en] To evaluate the safety and efficacy of reirradiation with carbon ions in patients with relapse of skull base chordoma and chondrosarcoma. Reirradiation with carbon ions was performed on 25 patients with locally recurrent skull base chordoma (n = 20) or chondrosarcoma (n = 5). The median time between the last radiation exposure and the reirradiation with carbon ions was 7 years. In the past, 23 patients had been irradiated once, two patients twice. Reirradiation was delivered using the active raster scanning method. The total median dose was 51.0 GyE carbon ions in a weekly regimen of five to six fractions of 3 GyE. Local progression-free survival (LPFS) was evaluated using the Kaplan-Meier method; toxicity was evaluated using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03). The treatment could be finished in all patients without interruption. In 80 % of patients, symptom control was achieved after therapy. The 2-year-LPFS probability was 79.3 %. A PTV volume of < 100 ml or a total dose of > 51 GyE was associated with a superior local control rate. The therapy was associated with low acute toxicity. One patient developed grade 2 mucositis during therapy. Furthermore, 12 % of patients had tympanic effusion with mild hypacusis (grade 2), while 20 % developed an asymptomatic temporal lobe reaction after treatment (grade 1). Only one patient showed a grade 3 osteoradionecrosis. Reirradiation with carbon ions is a safe and effective method in patients with relapsed chordoma and chondrosarcoma of the skull base. (orig.)
[de]
Evaluierung der Sicherheit und Wirksamkeit einer Re-Bestrahlung mittels Kohlenstoffionen bei Patienten mit Lokalrezidiv eines Chordoms und Chondrosarkoms der Schaedelbasis. Bei 25 Patienten mit einem Lokalrezidiv eines Chordoms (n = 20) oder Chondrosarkoms (n = 5) der Schaedelbasis erfolgte eine Re-Bestrahlung mittels Kohlenstoffionen. Die mediane Zeit zwischen letzter Bestrahlung und Re-Bestrahlung mit Kohlenstoffionen betrug 7 Jahre. Hierbei hatten 23 Patienten eine Bestrahlung und 2 Patienten zwei Bestrahlungen in der Vergangenheit erhalten. Die Re-Bestrahlung mit Kohlenstoffionen in aktiver Strahlapplikation erfolgte mit einer medianen Gesamtdosis von 51 GyE in einer woechentlichen Fraktionierung von 5-6 x 3 GyE. Das lokal progressionsfreie Ueberleben (LPFS) wurde mit Hilfe der Kaplan-Meier-Methode bestimmt. Zur Toxizitaetsbestimmung wurden die Kriterien des NCI CTCAE v.4.03 (National Cancer Institute ''Common Terminology Criteria for Adverse Events'' Version 4.03) herangezogen. Die Therapie konnte bei allen Patienten ohne Unterbrechung durchgefuehrt werden. Bei 80 % der Patienten konnte durch die Behandlung eine Kontrolle der Symptome erreicht werden. Das lokal progressionsfreie Ueberleben nach 2 Jahren betrug 79,3 %. Patienten mit einem Planungszielvolumen (PTV) von < 100 ml oder einer Gesamtdosis von > 51 GyE wiesen eine bessere lokale Kontrolle auf. Die Therapie war mit einer niedrigen Akuttoxizitaet verbunden. Ein Patient hatte waehrend der Behandlung eine Mukositis II. Bei 12 % der Patienten zeigte sich ein Paukenerguss mit leichter Hypakusis (CTC II). Eine asymptomatische Temporallappenreaktion wurde bei 20 % der Patienten nach Therapie im MRT nachgewiesen (CTC I). Ein Patient entwickelte eine Osteoradionekrose (CTC III). Die Re-Bestrahlung von Patienten mit Lokalrezidiv eines Chordoms und Chondrosarkoms der Schaedelbasis stellt eine sichere und effektive Methode dar. (orig.)Journal
[en] To evaluate feasibility and toxicity of carbon ion therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalation which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon ion therapy offers the advantage of sharp dose gradients promising increased dose application without increase of side-effects. Twenty-nine patients with various sinonasal malignancies were treated from 11/2009 to 08/2010. Accompanying toxicity was evaluated according to CTCAE v.4.0. Tumor response was assessed according to RECIST. Seventeen patients received treatment as definitive RT, 9 for local relapse, 2 for re-irradiation. All patients had T4 tumours (median CTV1 129.5 cc, CTV2 395.8 cc), mostly originating from the maxillary sinus. Median dose was 73 GyE mostly in mixed beam technique as IMRT plus carbon ion boost. Median follow- up was 5.1 months [range: 2.4 - 10.1 months]. There were 7 cases with grade 3 toxicity (mucositis, dysphagia) but no other higher grade acute reactions; 6 patients developed grade 2 conjunctivits, no case of early visual impairment. Apart from alterations of taste, all symptoms had resolved at 8 weeks post RT. Overall radiological response rate was 50% (CR and PR). Carbon ion therapy is feasible; despite high doses, acute reactions were not increased and generally resolved within 8 weeks post radiotherapy. Treatment response is encouraging though follow-up is too short to estimate control rates or evaluate potential late effects. Controlled trials are warranted
Journal
Radiation Oncology (Online); ISSN 1748-717X; ; v. 6; p. 30
; v. 6; p. 30
[en] Ameloblastic carcinomas are rare odontogenic tumors. Treatment usually consists of surgical resection and sometimes adjuvant radiation. We report the case of a 71 year-old male patient undergoing carbon ion therapy for extensive local relapse of ameloblastic carcinoma. Treatment outcome was favourable with a complete remission at 6 weeks post completion of radiotherapy while RT-treatment itself was tolerated well with only mild side effects. High dose radiation hence is a potential alternative for patients unfit or unwilling to undergo extensive surgery or in cases when only a subtotal resection is planned or the resection is mutilating
Journal
Radiation Oncology (Online); ISSN 1748-717X; ; v. 6; p. 13
; v. 6; p. 13
[en] To investigate toxicity and efficacy in high-risk malignant salivary gland tumors (MSGT) of the head and neck. Local control in R2-resected adenoid cystic carcinoma was already improved with a combination of IMRT and carbon ion boost at only mild side-effects, hence this treatment was also offered to patients with MSGT and microscopic residual disease (R1) or perineural spread (Pn+). From November 2009, all patients with MSGT treated with carbon ion therapy were evaluated. Acute side effects were scored according to CTCAE v.4.03. Tumor response was assessed according to RECIST where applicable. 103 patients were treated from 11/2009 to 03/2011, median follow-up is 6 months. 60 pts received treatment following R2 resections or as definitive radiation, 43 patients received adjuvant radiation for R1 and/or Pn+. 16 patients received carbon ion treatment for re-irradiation. Median total dose was 73.2 GyE (23.9 GyE carbon ions + 49,9 Gy IMRT) for primary treatment and 44.9 GyE carbon ions for re-irradiation. All treatments were completed as planned and generally well tolerated with no > CTC°III toxicity. Rates of CTC°III toxicity (mucositis and dysphagia) were 8.7% with side-effects almost completely resolved at first follow-up. 47 patients showed good treatment responses (CR/PR) according to RECIST. Acute toxicity remains low in IMRT with carbon ion boost also in R1-resected patients and patients undergoing re-irradiation. R2-resected patients showed high rates of treatment response, though follow-up is too short to assess long-term disease control
Journal
Radiation Oncology (Online); ISSN 1748-717X; ; v. 6; p. 149
; v. 6; p. 149
[en] Background: Treatment of surgically unresectable recurrence in the head and neck region remains a therapeutic problem with the only curative option being a second course of radiation with a tumouricidal dose. We report initial toxicity and efficacy of charged particle therapy in this situation. Methods: Treatment-related side-effects of patients treated with charged particle beams for recurrent tumours of the head and neck were prospectively collected and patient data was retrospectively analysed with regard to toxicity and efficacy of the treatment according to CTCAE v. 4.03 and RECIST. Results: Treatment was tolerated well without any severe acute toxicity. In non-chordoma/chondrosarcoma patients, overall response rate was 53.3% at 8 weeks post RT. 4/5 chordoma/chondrosarcoma patients showed no signs of further tumour progression. Conclusion: Initial experience of re-irradiation with scanned particle beams in recurrent tumours of the head and neck seems feasible and encouraging. Further follow-up is needed to investigate potential late effects.
Journal
[en] Highlights: • First experimental quantification of SPR prediction variation in 17 European centres. • Large inter-centre SPR variation of up to 9% for bones in the head observed. • Variation in range prediction on the magnitude of current clinical safety margins. • Observed variation stress the need for a common standard in SPR prediction. Experimental assessment of inter-centre variation and absolute accuracy of stopping-power-ratio (SPR) prediction within 17 particle therapy centres of the European Particle Therapy Network.
Journal
| 1 | 2 | Next |